Journal ArticleDOI
Rituximab and immune deficiency: case series and review of the literature.
Blanka Kaplan,Blanka Kaplan,Blanka Kaplan,Yelena Kopyltsova,Amrita Khokhar,Amrita Khokhar,Fung Lam,Vincent R. Bonagura +7 more
TLDR
There are patients with persistent B-cell dysfunction long after rituximab treatment was discontinued, and these patients should be distinguished from patients with primary immunodeficiency diseases.About:
This article is published in The Journal of Allergy and Clinical Immunology: In Practice.The article was published on 2014-09-01. It has received 93 citations till now. The article focuses on the topics: Immunodeficiency & Primary immunodeficiency.read more
Citations
More filters
Journal ArticleDOI
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez,Jordan S. Orange,Francisco A. Bonilla,Javier Chinen,Ivan K. Chinn,Morna J. Dorsey,Yehia El-Gamal,Terry Harville,Elham Hossny,Bruce Mazer,Robert P. Nelson,Elizabeth Secord,Stanley C. Jordan,E. Richard Stiehm,Ashley Vo,Mark Ballow +15 more
TL;DR: This work provides an update of the evidence‐based guideline on immunoglobulin therapy, last published in 2006, and suggests that careful consideration of its indications and administration is warranted.
Journal ArticleDOI
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
TL;DR: Monitoring routine serum immunoglobulin levels before and after rituximab therapy may help identify patients at high risk for developing infections and who may benefit from immunoglobeulin replacement therapy.
Journal ArticleDOI
Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
TL;DR: Here, the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia is reviewed, with special regard for subcutaneous administration route, to find a safe, effective, and well-tolerated treatment approach.
Journal ArticleDOI
When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach
TL;DR: This review describes a practical approach to the clinical, laboratory and radiological assessment of patients with antibody deficiency, focusing on the factors that determine whether or not immunoglobulin replacement should be used.
Journal ArticleDOI
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.
TL;DR: The evidence supporting the association of specific risk factors with the development of hypogammaglobulinemia and infections post-RTX is summarized to define a personalized evidence-based risk management plan for patients treated with RTX.
References
More filters
Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Journal ArticleDOI
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C. W. Edwards,Leszek Szczepanski,Jacek Szechiński,Anna Filipowicz-Sosnowska,Paul Emery,D. Close,Randall M Stevens,T. Shaw +7 more
TL;DR: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotRexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Journal ArticleDOI
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley Cohen,Paul Emery,Maria Greenwald,Maxime Dougados,Richard Furie,Mark C. Genovese,Edward C. Keystone,J.E. Loveless,Gerd-Rüdiger Burmester,M. Cravets,E. W. Hessey,T. Shaw,Mark C. Totoritis +12 more
TL;DR: At 24 weeks, a single course of rituximab with concomitant MTX therapy provided significant and clinically meaningful improvements in disease activity in patients with active, longstanding RA who had an inadequate response to 1 or more anti-TNF therapies.
Journal ArticleDOI
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Paul Emery,Roy Fleischmann,Anna Filipowicz-Sosnowska,Joy Schechtman,Leszek Szczepanski,Arthur Kavanaugh,Artur Racewicz,Ronald F van Vollenhoven,Nicole F. Li,Sunil Agarwal,E. W. Hessey,T. Shaw +11 more
TL;DR: Both rituximab doses were effective and well tolerated when added to MTX therapy in patients with active rheumatoid arthritis, although intravenous glucocorticoid premedication improved tolerability during the first ritUXimab infusion.
Journal ArticleDOI
Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia
Laurie H. Sehn,Jane Donaldson,Mukesh Chhanabhai,Catherine Fitzgerald,Karamjit Gill,Richard Klasa,Nicol Macpherson,Susan E. O'Reilly,John J. Spinelli,Judy Sutherland,Kenneth S. Wilson,Randy D. Gascoyne,Joseph M. Connors +12 more
TL;DR: In this paper, the authors conducted a population-based analysis to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC).